Merck & Co. Inc. diskutieren

Merck & Co., Inc. (NYSE: MRK) had its price target lowered by analysts at UBS Group AG from $148.00 to $142.00. They now have a "buy" rating on the stock.

Merck & Co., Inc. (NYSE: MRK) had its price target lowered by analysts at Bank of America Co. from $150.00 to $145.00. They now have a "buy" rating on the stock.

Merck & Co., Inc. (NYSE: MRK) had its price target lowered by analysts at Barclays PLC from $145.00 to $142.00. They now have an "overweight" rating on the stock.

Merck & Co., Inc. (NYSE: MRK) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $155.00 price target on the stock.

Merck & Co., Inc. (NYSE: MRK) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $155.00 price target on the stock.

Merck & Co., Inc. (NYSE: MRK) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $155.00 price target on the stock.

Merck & Co., Inc. (NYSE: MRK) had its price target lowered by analysts at Barclays PLC from $142.00 to $140.00. They now have an "overweight" rating on the stock.

Merck & Co., Inc. (NYSE: MRK) had its price target lowered by analysts at Truist Financial Co. from $143.00 to $132.00. They now have a "buy" rating on the stock.

Merck & Co., Inc. (NYSE: MRK) had its price target lowered by analysts at Citigroup Inc. from $140.00 to $130.00. They now have a "buy" rating on the stock.

Merck looks like a solid buy right now. Their cancer drug Keytruda is an absolute beast, raking in over $7 billion in Q2 alone - that's some serious cash flow! And they're not resting on their laurels either. With new vaccine approvals like CAPVAXIVE and ventures into ophthalmology, Merck is diversifying nicely. Sure, Keytruda's patent expiration in 2028 is a bit of a cloud on the horizon, but their promising pipeline and robust earnings growth more than make up for it. Plus, with a forward P/E of just 11.19, Merck seems undervalued compared to peers. The recent dip looks like a great buying opportunity for this blue-chip pharma giant. What's not to like?

Merck & Co., Inc. (NYSE: MRK) had its price target lowered by analysts at BMO Capital Markets from $150.00 to $136.00. They now have an "outperform" rating on the stock.

Merck & Co., Inc. (NYSE: MRK) had its price target lowered by analysts at Guggenheim from $137.00 to $130.00. They now have a "buy" rating on the stock.

Merck & Co., Inc. (NYSE: MRK) had its price target lowered by analysts at Truist Financial Co. from $132.00 to $130.00. They now have a "buy" rating on the stock.

Looks like Merck's hit a speed bump, folks. The pharma giant's recent guidance cut has sent shivers down investors' spines, and it's not hard to see why. Their diabetes drugs and HPV vaccine sales are lagging behind expectations, which is like showing up to a potluck with a half-baked casserole. It's got me wondering if Merck's recipe for success needs some tweaking. While they're still a heavyweight in the pharma world, this stumble could be a sign of tougher times ahead. Maybe it's time to consider trimming our positions and wait for Merck to get its mojo back. After all, in the stock market rollercoaster, sometimes it's smart to hop off before the big dip, right?

Merck & Co., Inc. (NYSE: MRK) was upgraded by analysts at HSBC Holdings plc from a "hold" rating to a "buy" rating. They now have a $130.00 price target on the stock.

Merck & Co., Inc. (NYSE: MRK) had its price target lowered by analysts at UBS Group AG from $125.00 to $120.00. They now have a "buy" rating on the stock.

Merck & Co., Inc. (NYSE: MRK) had its price target lowered by analysts at Leerink Partners from $136.00 to $119.00. They now have an "outperform" rating on the stock.

Merck & Co., Inc. (NYSE: MRK) had its price target lowered by analysts at Citigroup Inc. from $130.00 to $125.00. They now have a "buy" rating on the stock.

Merck & Co., Inc. (NYSE: MRK) had its price target lowered by analysts at Citigroup Inc. from $125.00 to $115.00. They now have a "buy" rating on the stock.

Merck & Co., Inc. (NYSE: MRK) had its price target lowered by analysts at Bank of America Co. from $118.00 to $112.00. They now have a "buy" rating on the stock.